Published in Am J Pathol on May 01, 1991
The plasminogen activator/plasmin system. J Clin Invest (1991) 4.20
The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest (1995) 3.00
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J (1992) 2.65
Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut (1996) 2.63
The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol (1994) 1.79
Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol (1993) 1.71
Urokinase type plasminogen activator receptor expression in colorectal neoplasms. Gut (1998) 1.50
A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J (1997) 1.47
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer (1997) 1.47
Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem (2009) 1.44
Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer (1994) 1.43
Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol (1994) 1.38
Protease-activated drug development. Theranostics (2012) 1.36
Interleukin 8: cells of origin in inflammatory bowel disease. Gut (1996) 1.35
In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol (1991) 1.33
Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis. Cancer Res (2007) 1.29
Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol (1997) 1.27
Proteolysis in human breast and colorectal cancer. Br J Cancer (1999) 1.27
High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci U S A (1994) 1.26
Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol (1991) 1.23
Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness. Mol Biol Cell (2004) 1.22
Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest (1995) 1.17
Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells. Clin Exp Metastasis (1998) 1.15
Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem J (1995) 1.11
Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol (1994) 1.07
SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int J Oncol (2006) 1.06
Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J Clin Invest (1996) 1.06
Tumor stroma as targets for cancer therapy. Pharmacol Ther (2012) 1.06
Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res (2007) 1.05
Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Pathol (1995) 1.03
Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul (1991) 1.03
Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol (2000) 1.00
Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer (1995) 0.99
Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells. EMBO J (1991) 0.99
Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis (1998) 0.98
A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest (1993) 0.94
Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines. PLoS One (2010) 0.94
Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor. J Biol Chem (2011) 0.94
Mechanisms for the control of matriptase activity in the absence of sufficient HAI-1. Am J Physiol Cell Physiol (2011) 0.92
Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion. Br J Cancer (2001) 0.91
Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization. Am J Pathol (1999) 0.89
Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin Exp Metastasis (1998) 0.89
Proteolysis in colorectal cancer. Mol Pathol (1999) 0.89
In vivo and in vitro invasion in relation to phenotypic characteristics of human colorectal carcinoma cells. Br J Cancer (1995) 0.89
Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization. Am J Pathol (1995) 0.89
In vitro modulation of MMP-2 and MMP-9 in adult human sarcoma cell lines by cytokines, inducers and inhibitors. Int J Oncol (2013) 0.88
Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies. Br J Cancer (1999) 0.87
Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest (1995) 0.87
In vitro modulation of MMP-2 and MMP-9 in pediatric human sarcoma cell lines by cytokines, inducers and inhibitors. Int J Oncol (2013) 0.86
Regulation of u-PAR gene expression by H2A.Z is modulated by the MEK-ERK/AP-1 pathway. Nucleic Acids Res (2011) 0.86
Targeting zymogen activation to control the matriptase-prostasin proteolytic cascade. J Med Chem (2011) 0.84
Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. Br J Cancer (1998) 0.84
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. BMC Cancer (2014) 0.83
Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. Br J Cancer (1999) 0.82
Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am J Pathol (1995) 0.82
Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry. Br J Cancer (1998) 0.81
Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas. Br J Cancer (1998) 0.81
In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas. Am J Pathol (1997) 0.81
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol (2000) 0.80
Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. Am J Pathol (1997) 0.80
Cathepsin B and other proteases in human colorectal carcinoma. Am J Pathol (1994) 0.80
Urokinase and the intestinal mucosa: evidence for a role in epithelial cell turnover. Gut (1998) 0.79
Multi-Target Approaches in Colon Cancer Chemoprevention Based on Systems Biology of Tumor Cell-Signaling. Gene Regul Syst Bio (2008) 0.79
p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading. BMC Cancer (2016) 0.79
Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases. J Oncol (2012) 0.78
Time-dependent biological differences in molecular markers of high-grade urothelial cancer over 7 decades (ras proteins, pTEN, uPAR, PAI-1 and MMP-9). Virchows Arch (2012) 0.77
Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. Br J Cancer (1996) 0.76
Low interleukin-1alpha messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma. Br J Cancer (2001) 0.76
A model to explain specific cellular communications and cellular harmony:- a hypothesis of coupled cells and interactive coupling molecules. Theor Biol Med Model (2014) 0.76
Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth. BMC Cancer (2002) 0.75
The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis. Oncotarget (2017) 0.75
Three types of human lung tumour cell lines can be distinguished according to surface expression of endogenous urokinase and their capacity to bind exogenous urokinase. Br J Cancer (1992) 0.75
Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine. Biomark Insights (2016) 0.75
Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin. Biochem J (1993) 0.75
Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma. Oncotarget (2017) 0.75
A retrospective study of urokinase-type plasminogen activator receptor (uPAR) as a prognostic factor in cancer of the uterine cervix. Int J Clin Oncol (2014) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res (1985) 8.64
A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol (1985) 3.62
Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J (1990) 3.27
Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci U S A (1985) 2.72
Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol (1988) 2.69
Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol (1987) 2.63
The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol (1990) 2.36
Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol (1990) 2.33
Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta (1987) 2.06
Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol (1988) 1.97
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol (1989) 1.93
Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol (1990) 1.91
Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. Int J Cancer (1984) 1.72
Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res (1990) 1.68
Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res (1988) 1.56
Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res (1989) 1.55
Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem (1990) 1.52
Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem (1986) 1.51
Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol (1991) 1.50
Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem (1986) 1.49
Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin. J Cell Biol (1988) 1.49
A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem (1988) 1.49
The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem (1990) 1.43
Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol (1984) 1.40
Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J Invest Dermatol (1988) 1.32
Immunohistochemical localization of urokinase- and tissue-type plasminogen activators in psoriatic skin. J Invest Dermatol (1987) 1.28
Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization. J Histochem Cytochem (1991) 1.17
Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer (1986) 1.10
Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res (1988) 1.06
The urokinase type of plasminogen activator in cancer of digestive tracts. Thromb Res (1988) 1.06
Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells. J Biol Chem (1990) 1.05
Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme. Int J Cancer (1988) 0.98
Plasminogen activator content of human colon tumors and normal mucosae: separation of enzymes and partial purification. J Natl Cancer Inst (1980) 0.97
Urokinase receptors in human monocytes. Biochim Biophys Acta (1990) 0.96
Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry (1990) 0.96
Urokinase-type plasminogen activator in endothelial cells during acute inflammation of the appendix. Am J Pathol (1989) 0.91
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence? Gut (1987) 0.90
Urokinase-type plasminogen activator is increased in the involuting ventral prostate of castrated rats. Endocrinology (1990) 0.89
Localization of urokinase-type plasminogen activator receptor on U937 cells: phorbol ester PMA induces heterogeneity. Exp Cell Res (1990) 0.83
Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res (1985) 8.64
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology (2002) 4.22
125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic? Eur Respir J (2007) 3.67
Guidelines for the management of adult lower respiratory tract infections. Eur Respir J (2005) 3.51
Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J (1990) 3.27
Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect (2011) 2.99
Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development (1996) 2.88
Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol (2001) 2.80
The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem (1987) 2.73
Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci U S A (1985) 2.72
Nucleotide sequence of the attenuator region of the histidine operon of Escherichia coli K-12. Proc Natl Acad Sci U S A (1978) 2.71
Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem (1991) 2.68
Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J (1992) 2.65
Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol (1987) 2.63
Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem (1991) 2.61
Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell (1986) 2.38
The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res (1985) 2.14
The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A (2002) 2.14
Antibiotic prescribing for adults with acute cough/lower respiratory tract infection: congruence with guidelines. Eur Respir J (2011) 2.13
Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J (1987) 1.98
Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol (1988) 1.97
Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology (1999) 1.97
Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol (1998) 1.95
Application of a computerised method to measure static pressure volume curve in acute respiratory distress syndrome. Intensive Care Med (2000) 1.95
Prep1, a novel functional partner of Pbx proteins. EMBO J (1998) 1.94
The subcellular localization of PBX1 and EXD proteins depends on nuclear import and export signals and is modulated by association with PREP1 and HTH. Genes Dev (1999) 1.93
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res (1995) 1.93
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol (1989) 1.93
The novel homeoprotein Prep1 modulates Pbx-Hox protein cooperativity. EMBO J (1998) 1.93
Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J (1990) 1.87
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res (1993) 1.86
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry (1982) 1.85
Detection of T cells in paraffin wax embedded tissue using antibodies against a peptide sequence from the CD3 antigen. J Clin Pathol (1989) 1.85
A novel complex between the p65 subunit of NF-kappa B and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J (1992) 1.81
Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. Proc Natl Acad Sci U S A (1984) 1.80
Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med (2001) 1.79
The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol (1994) 1.79
Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol (1987) 1.79
Pain epidemiology and health related quality of life in chronic non-malignant pain patients referred to a Danish multidisciplinary pain center. Pain (1997) 1.75
Analysis of IMGSAC autism susceptibility loci: evidence for sex limited and parent of origin specific effects. J Med Genet (2005) 1.74
European union standards for tuberculosis care. Eur Respir J (2012) 1.73
Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol (1993) 1.71
Autotransplantation in vitiligo: treatment with epidermal grafts and cultured melanocytes. Acta Derm Venereol (1993) 1.71
Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res (1992) 1.71
Chlamydia pneumoniae: crossing the barriers? Eur Respir J (2004) 1.70
Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res (1988) 1.70
Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J (1996) 1.70
Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J (1999) 1.69
Segmental expression of Hoxb2 in r4 requires two separate sites that integrate cooperative interactions between Prep1, Pbx and Hox proteins. Development (2000) 1.69
Biochemical and regulatory properties of Escherichia coli K-12 hisT mutants. J Bacteriol (1977) 1.69
Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood (2000) 1.69
Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett (1986) 1.68
Structure and function of epidermal growth factor-like regions in proteins. FEBS Lett (1988) 1.66
Interaction between histidyl transfer ribonucleic acid and the first enzyme for histidine biosynthesis of Salmonella typhimurium. J Bacteriol (1970) 1.64
Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J (1997) 1.64
Implementing clinical guidelines in the treatment of diabetes mellitus in general practice. Evaluation of effort, process, and patient outcome related to implementation of a computer-based decision support system. Int J Technol Assess Health Care (2000) 1.64
Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst (1999) 1.64
Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res (2000) 1.60
Neutrophils express tumor necrosis factor-alpha during mouse skin wound healing. J Invest Dermatol (1995) 1.60
Neurosurgery for trigeminal neuralgia: comparison of alcohol block, neurectomy, and radiofrequency coagulation. Clin J Pain (1996) 1.58
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res (1994) 1.55
Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem (1992) 1.55
Blood neutrophil increment after a single injection of rhG-CSF or rhGM-CSF correlates with marrow cellularity and may predict the grade of neutropenia after chemotherapy. Br J Haematol (1993) 1.55
Cimetidine responders in non-ulcer dyspepsia. Scand J Gastroenterol (1988) 1.53
The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem (1991) 1.52
Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem (1990) 1.52
Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem (1986) 1.51
Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene (1998) 1.51
Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol (1991) 1.50
Isolation of transducing bacteriophages for the histidine and isoleucine-valine operons in Escherichia coli K-12. J Bacteriol (1972) 1.50
Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. J Biol Chem (1986) 1.49
A 55,000-60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J Biol Chem (1988) 1.49
Lactational competence and involution of the mouse mammary gland require plasminogen. Development (2000) 1.48
A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J (1997) 1.47
Screening of nine candidate genes for autism on chromosome 2q reveals rare nonsynonymous variants in the cAMP-GEFII gene. Mol Psychiatry (2003) 1.47